Literature DB >> 23067008

Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo.

Amber N Shatzer1, Michael Graham Espey, Mayra Chavez, Hongbin Tu, Mark Levine, Jeffrey I Cohen.   

Abstract

Ascorbic acid has been shown to kill various cancer cell lines at pharmacologic concentrations. We found that Epstein-Barr virus (EBV)-positive Burkitt lymphoma (BL) cells were more susceptible to ascorbic acid-induced cell killing than EBV-negative BL cells or EBV-transformed lymphoblastoid cells (LCLs). Ascorbic acid did not induce apoptosis in any of the tested cells but did induce the production of reactive oxygen species and cell death. Previously, we showed that bortezomib, a proteasome inhibitor, induces cell death in LCLs and EBV-positive BL cells. We found that ascorbic acid is strongly antagonistic for bortezomib-induced cell death in LCLs and EBV-positive BL cells. Finally, ascorbic acid did not prolong survival of severe combined immunodefiency mice inoculated with LCLs either intraperitoneally or subcutaneously. Thus, while ascorbic acid was highly effective at killing EBV-positive BL cells and LCLs in vitro, it antagonized cell killing by bortezomib and was ineffective in an animal model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23067008      PMCID: PMC4055524          DOI: 10.3109/10428194.2012.739686

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  35 in total

Review 1.  Ascorbic acid and dehydroascorbic acid analyses in biological samples.

Authors:  P W Washko; R W Welch; K R Dhariwal; Y Wang; M Levine
Journal:  Anal Biochem       Date:  1992-07       Impact factor: 3.365

2.  Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues.

Authors:  Qi Chen; Michael Graham Espey; Murali C Krishna; James B Mitchell; Christopher P Corpe; Garry R Buettner; Emily Shacter; Mark Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

3.  Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.

Authors:  Wei Zou; Ping Yue; Na Lin; Min He; Zhongmei Zhou; Sagal Lonial; Fadlo R Khuri; Binghe Wang; Shi-Yong Sun
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

4.  Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.

Authors:  A K Chiang; Q Tao; G Srivastava; F C Ho
Journal:  Int J Cancer       Date:  1996-11-04       Impact factor: 7.396

5.  Epstein-Barr virus in AIDS-related primary central nervous system lymphoma.

Authors:  E M MacMahon; J D Glass; S D Hayward; R B Mann; P S Becker; P Charache; J C McArthur; R F Ambinder
Journal:  Lancet       Date:  1991-10-19       Impact factor: 79.321

6.  Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells.

Authors:  M Sugiura; S Imai; M Tokunaga; S Koizumi; M Uchizawa; K Okamoto; T Osato
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

7.  Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-associated Tumors.

Authors:  D Rea; H J Delecluse; S J Hamilton-Dutoit; L Marelle; I Joab; L Edelman; J F Finet; M Raphael
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

8.  Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.

Authors:  S J Hamilton-Dutoit; D Rea; M Raphael; K Sandvej; H J Delecluse; C Gisselbrecht; L Marelle; H J van Krieken; G Pallesen
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

9.  Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein.

Authors:  S Imai; S Koizumi; M Sugiura; M Tokunaga; Y Uemura; N Yamamoto; S Tanaka; E Sato; T Osato
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

10.  Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma.

Authors:  R Pathmanathan; U Prasad; R Sadler; K Flynn; N Raab-Traub
Journal:  N Engl J Med       Date:  1995-09-14       Impact factor: 91.245

View more
  10 in total

1.  Sodium ascorbate kills Candida albicans in vitro via iron-catalyzed Fenton reaction: importance of oxygenation and metabolism.

Authors:  Pinar Avci; Fernanda Freire; Andras Banvolgyi; Eleftherios Mylonakis; Norbert M Wikonkal; Michael R Hamblin
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

2.  Survey on the worldwide Chronic Myeloid Leukemia Advocates Network regarding complementary and alternative medicine.

Authors:  Thomas Elsner; Ralph Muecke; Oliver Micke; Franz J Prott; Karsten Muenstedt; Anita Waldmann; Jan Geissler; Jutta Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-16       Impact factor: 4.553

3.  Calculated cell-specific intracellular hydrogen peroxide concentration: Relevance in cancer cell susceptibility during ascorbate therapy.

Authors:  Dieanira Erudaitius; Jacqueline Mantooth; Andrew Huang; Jesse Soliman; Claire M Doskey; Garry R Buettner; Victor G J Rodgers
Journal:  Free Radic Biol Med       Date:  2018-03-27       Impact factor: 7.376

4.  Multiple Defects Impair the HLA Class II Antigen Presentation Capacity of Burkitt Lymphoma.

Authors:  Jason M God; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2016-08-05

5.  Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy.

Authors:  Claire M Doskey; Visarut Buranasudja; Brett A Wagner; Justin G Wilkes; Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Redox Biol       Date:  2016-10-28       Impact factor: 11.799

Review 6.  New insights into redox homeostasis as a therapeutic target in B-cell malignancies.

Authors:  Agnieszka Graczyk-Jarzynka; Radoslaw Zagozdzon; Angelika Muchowicz; Marta Siernicka; Przemyslaw Juszczynski; Malgorzata Firczuk
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

Review 7.  Burkitt lymphoma in adolescents and young adults: management challenges.

Authors:  Massimo Dozzo; Francesca Carobolante; Pietro Maria Donisi; Annamaria Scattolin; Elena Maino; Rosaria Sancetta; Piera Viero; Renato Bassan
Journal:  Adolesc Health Med Ther       Date:  2016-12-23

8.  Peroxiporin Expression Is an Important Factor for Cancer Cell Susceptibility to Therapeutic H2O2: Implications for Pharmacological Ascorbate Therapy.

Authors:  Dieanira Erudaitius; Andrew Huang; Sarah Kazmi; Garry R Buettner; Victor G J Rodgers
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

9.  Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate.

Authors:  Agnieszka Graczyk-Jarzynka; Agnieszka Goral; Angelika Muchowicz; Radoslaw Zagozdzon; Magdalena Winiarska; Malgorzata Bajor; Anna Trzeciecka; Klaudyna Fidyt; Joanna Alicja Krupka; Julia Cyran; Kacper Szczygiel; Dimitar G Efremov; Stefania Gobessi; Adam Jagielski; Karolina Siudakowska; Malgorzata Bobrowicz; Marta Klopotowska; Joanna Barankiewicz; Agata Malenda; Ewa Lech-Maranda; Nina Miazek-Zapala; Piotr Henryk Skarzynski; Antoni Domagala; Jakub Golab; Malgorzata Firczuk
Journal:  Redox Biol       Date:  2018-11-29       Impact factor: 11.799

10.  CYB561A3 is the key lysosomal iron reductase required for Burkitt B-cell growth and survival.

Authors:  Zhonghao Wang; Rui Guo; Stephen J Trudeau; Emma Wolinsky; Tslil Ast; Jin Hua Liang; Chang Jiang; Yijie Ma; Mingxiang Teng; Vamsi K Mootha; Benjamin E Gewurz
Journal:  Blood       Date:  2021-12-02       Impact factor: 25.476

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.